NT 0400
Alternative Names: NT-0400Latest Information Update: 28 Oct 2022
At a glance
- Originator Neos Therapeutics
- Developer Aytu BioPharma
- Class Antiemetics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Nausea and vomiting
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for preclinical development in Nausea and vomiting in USA (PO, Controlled release)
- 22 Mar 2021 Neos Therapeutics has merged with Aytu BioScience to form Aytu BioPharma
- 16 Apr 2019 Neos Therapeutics plans a clinical trial for Nausea and vomiting in 2019